Origin and evolution of patents and trademarks in sports biomechanics

La Biomecánica es una disciplina científica cuyo origen se remonta varios siglos atrás, cuando distintos precursores utilizaron diferentes ciencias para analizar el movimiento humano y animal. El desarrollo tecnológico ha propiciado la invención de distintos dispositivos los cuales han sido utilizados en estudios biomecánicos. Dichos dispositivos han facilitado la toma y análisis de datos relacionados con el movimiento y sus causas. La Oficina Española de Patentes y Marcas (O.E.P.M.) es el organismo encargado de registrar y patentar las invenciones en España. Para ello, la patente presentada debe de cumplir con unos requisitos y superar una evaluación técnica. Actualmente podemos encontrar distintas patentes para realizar análisis cinemáticos y cinéticos del movimiento, formadas por emisores y receptores de láser, cámaras de alta velocidad, sensores de presión, etc. Numerosas investigaciones relacionadas con la biomecánica deportiva utilizan estos dispositivos para obtener datos más precisos, mejorando la calidad de la investigación y, en algunos casos, posibilitando la mejora del rendimiento físico y/o deportivo. El propósito del presente artículo, consiste en exponer la evolución de la biomecánica en general, y deportiva en particular, realizando una revisión sobre patentes relacionadas con la biomecánica del deporte, y reflejar cómo y donde registrar las invenciones. Para ello se han utilizado las plataformas digitales y bases de datos Esp@cenet, Invesnes para la revisión de patentes con origen español y, Google Patent para patentes registradas en oficinas de fuera de España

Estudio preliminar de la activación neuromuscular corriendo descalzo y calzado

The aim of this preliminary study was to compare the influence of footwear and the fatigue state on the muscle activity of the tibialis anterior, peroneus longus, gastrocnemius medialis and gastrocnemius lateralis. For this purpose, 7 participants ran a 20-min fatiguing run on a treadmill at 1% slope at 75% of their individual maximal aerobic speed. Muscle activation was measured twice during 30 seconds before and after the fatiguing run while running shod and barefoot. Before the fatiguing run, running barefoot led to a greater activation of the peroneus longus compared to running shod. When running fatigued, running barefoot also increased the activation of the tibialis anterior compared to running shod. Moreover, the fatigue state decreased the gastrocnemius medialis activity when running shod.El objetivo del presente estudio preliminar fue comparar la actividad muscular de los músculos tibial anterior, peroneo lateral largo, gastrocnemio medial ygastrocnemio lateral entre la carrera con y sin calzado, y la influencia de la fatiga. 7 participantes realizaron una carrera de fatiga de 20 minutos al 75% de su velocidad aeróbica máxima en cinta con 1% de pendiente. Se midió la actividad mioeléctrica de los músculos antes mencionados tanto antes como después de la prueba de fatiga en dos condiciones: con calzado y sin calzado. Los resultadosmostraron una mayor actividad del tibial anterior durante la carrera en fatiga descalzo respecto a la carrera calzado y una mayor actividad del peroneo lateral largo durante la carrera sin fatiga descalzo. Por otra parte, también se encontró una menoractividad del gastrocnemio medial durante la carrera con zapatillas y en fatiga respecto a la carrera sin fatiga

UPMSat-2 Micro-Satellite: In-orbit Technological Demonstration for Education and Science

The UPMSat-2 micro-satellite was launched on September the 3rd 2020 at 01:51:10 UTC from Kourou spaceport in French Guyana. The VV16 Vega Flight has been the first low Earth orbit rideshare commercial flight with a total of 53 satellites (7 of them micro-satellites) to be released by the launch vehicle, arranged in the modular SSMS (Small Spacecraft Mission Service) dispenser. UPMSat-2 is an educational, scientific and in-orbit technological demonstration microsatellite project led by the IDR/UPM research institute from Universidad Politécnica de Madrid (UPM), Spain. This mission can be considered as a logical extension of the IDR/UPM Institute activities focused on designing small satellites to be used as educational platforms of first level. Thereby, UPMSat-2 (as well as its precursor, the UPMSat-1) has the main objective to give students the competences for designing, analyzing, manufacturing, integrating, testing and operating the platform. UPMSat-2 also includes a set of scientific payloads and equipment to be tested in space, provided by research institutions and private companies. The UPMSat-2 is a 50 kg-class microsatellite developed for a 2-year LEO mission with a geometrical envelope of 0.5 x 0.5 x 0.6 m. Since launch, the satellite is orbiting the Earth in a sun-synchronous orbit of 500 km of altitude, passing over the IDR/UPM ground station four times a day. The satellite operation is being carried out by students and professors of the Master in Space Systems (MUSE), an official Master’s program of UPM organized by IDR/UPM. This work describes the most relevant characteristics of UPMSat-2, its payloads, technological contributions, and the main activities performed up to the launch, including participation in the launch campaign in French Guyana. The lessons learned during the mission are also summarized. Finally, the importance and benefits of incorporating actual space systems design and development within academic programs is also emphasized, as it improves these programs with constant and direct feedback

Repeated Aspergillusisolation in respiratory samples from non-immunocompromised patients not selected based on clinical diagnoses: colonisation or infection?

Background: Isolation of Aspergillus from lower respiratory samples is associated with colonisation in high percentage of cases, making it of unclear significance. This study explored factors associated with diagnosis (infection vs. colonisation), treatment (administration or not of antifungals) and prognosis (mortality) in non-transplant/non-neutropenic patients showing repeated isolation of Aspergillus from lower respiratory samples. Methods: Records of adult patients (29 Spanish hospitals) presenting ≥2 respiratory cultures yielding Aspergillus were retrospectively reviewed and categorised as proven (histopathological confirmation) or probable aspergillosis (new respiratory signs/symptoms with suggestive chest imaging) or colonisation (symptoms not attributable to Aspergillus without dyspnoea exacerbation, bronchospasm or new infiltrates). Logistic regression models (step-wise) were performed using Aspergillosis (probable + proven), antifungal treatment and mortality as dependent variables. Significant (p < 0.001) models showing the highest R2 were considered. Results: A total of 245 patients were identified, 139 (56.7%) with Aspergillosis. Aspergillosis was associated (R2 = 0.291) with ICU admission (OR = 2.82), congestive heart failure (OR = 2.39) and steroids pre-admission (OR = 2.19) as well as with cavitations in X-ray/CT scan (OR = 10.68), radiological worsening (OR = 5.22) and COPD exacerbations/need for O2 interaction (OR = 3.52). Antifungals were administered to 79.1% patients with Aspergillosis (100% proven, 76.8% probable) and 29.2% colonised, with 69.5% patients receiving voriconazole alone or in combination. In colonised patients, administration of antifungals was associated with ICU admission at hospitalisation (OR = 12.38). In Aspergillosis patients its administration was positively associated (R2 = 0.312) with bronchospasm (OR = 9.21) and days in ICU (OR = 1.82) and negatively with Gold III + IV (OR = 0.26), stroke (OR = 0.024) and quinolone treatment (OR = 0.29). Mortality was 78.6% in proven, 41.6% in probable and 12.3% in colonised patients, and was positively associated in Aspergillosis patients (R2 = 0.290) with radiological worsening (OR = 3.04), APACHE-II (OR = 1.09) and number of antibiotics for treatment (OR = 1.51) and negatively with species other than A. fumigatus (OR = 0.14) and aspergillar tracheobronchitis (OR = 0.27). Conclusions: Administration of antifungals was not always closely linked to the diagnostic categorisation (colonisation vs. Aspergillosis), being negatively associated with severe COPD (GOLD III + IV) and concomitant treatment with quinolones in patients with Aspergillosis, probably due to the similarity of signs/symptoms between this entity and pulmonary bacterial infections

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Preliminary study of the neuromuscular activation during barefoot and shod running

El objetivo del presente estudio preliminar fue comparar la actividad muscular de los músculos tibial anterior, peroneo lateral largo, gastrocnemio medial y gastrocnemio lateral entre la carrera con y sin calzado, y la influencia de la fatiga. 7 participantes realizaron una carrera de fatiga de 20 minutos al 75% de su velocidad aeróbica máxima en cinta con 1% de pendiente. Se midió la actividad mioeléctrica de los músculos antes mencionados tanto antes como después de la prueba de fatiga en dos condiciones: con calzado y sin calzado. Los resultados mostraron una mayor actividad del tibial anterior durante la carrera en fatiga descalzo respecto a la carrera calzado y una mayor actividad del peroneo lateral largo durante la carrera sin fatiga descalzo. Por otra parte, también se encontró una menor actividad del gastrocnemio medial durante la carrera con zapatillas y en fatiga respecto a la carrera sin fatiga